Markets:

Overview

News

Currencies

International

Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

46.33 -0.40 (-0.86%)

Streaming Delayed Price Updated: 2:05 PM EDT, Apr 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Scholar Rock to Present at the BofA Securities 2026 Health Care Conference

Today 8:00 EDT

From Scholar Rock

Via Business Wire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 17, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

March 31, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 13, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Holding Corp (NASDAQ:SRRK) Posts Q4 Loss, Awaits Apitegromab Approval in 2026 ↗

March 03, 2026

Via Chartmill

CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

March 03, 2026

From Scholar Rock

Via Business Wire

Scholar Rock (SRRK) Q4 2025 Earnings Transcript ↗

March 03, 2026

Scholar Rock (SRRK) Q4 2025 Earnings Transcript

Via The Motley Fool

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗

February 22, 2026

Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.

Via The Motley Fool

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗

February 22, 2026

This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.

Via The Motley Fool

Topics Regulatory Compliance

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗

February 22, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗

February 22, 2026

Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗

February 22, 2026

Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

Scholar Rock to Present at Upcoming Investor Conferences

February 18, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 13, 2026

From Scholar Rock

Via Business Wire

Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

February 10, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026 ↗

February 01, 2026

The Chief Scientific Officer of Scholar Rock Holding Corp has made multiple filings regarding disposals in January 2026, but this should not alarm investors.

Via The Motley Fool

Topics Regulatory Compliance

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026

From Scholar Rock

Via Business Wire

Scholar Rock Highlights 2026 Strategic Priorities

January 12, 2026

From Scholar Rock, Inc.

Via Business Wire

Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Scholar Rock, Inc.

Via Business Wire

Nasdaq Bears Dig In: Short Interest Hits Record 18.38 Billion Shares Amid Valuation Anxiety

December 24, 2025

As the final trading days of 2025 approach, the Nasdaq has reached a staggering milestone that has both bulls and bears on edge. According to the latest settlement data released on December 15, 2025,...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 13, 2025

From Scholar Rock

Via Business Wire

Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗

December 03, 2025

This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

Via The Motley Fool

Topics Regulatory Compliance

Scholar Rock to Present at Upcoming Investor Conferences

November 18, 2025

From Scholar Rock

Via Business Wire

Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session. ↗

November 14, 2025

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Via Chartmill

Why Is Scholar Rock Holding Stock Climbing Today? ↗

November 14, 2025

Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab.

Via Benzinga

Why Did Scholar Rock Soar 26% Today? ↗

November 14, 2025

The company is planning to reapply for approval of a muscle atrophy therapy in the coming year.

Via Stocktwits

Topics Earnings

Gold Tumbles Over 2%; Cidara Therapeutics Shares Spike Higher ↗

November 14, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 14, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.

Via Chartmill

Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday ↗

November 14, 2025

Via Benzinga

Scholar Rock Holding Corp (NASDAQ:SRRK) Posts Wider-Than-Expected Q3 2025 Loss Amid Key Launch Preparations ↗

November 14, 2025

Scholar Rock invests heavily in its lead drug apitegromab, targeting a 2026 launch for spinal muscular atrophy despite a wider Q3 2025 loss.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.